7 results on '"Tancevski, Ivan"'
Search Results
2. Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.
- Author
-
Jäger, Michael, Diem, Gabriel, Sahanic, Sabina, Fux, Vilmos, Griesmacher, Andrea, Lass-Flörl, Cornelia, Wilflingseder, Doris, Tancevski, Ivan, and Posch, Wilfried
- Subjects
SARS-CoV-2 ,SARS-CoV-2 Omicron variant ,MONONUCLEAR leukocytes ,BOOSTER vaccines - Abstract
Background The emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants BA.1, BA.2, and BA.4/5 demonstrate higher transmission and infection rates than previous variants of concern. To evaluate effectiveness of heterologous and homologous booster vaccination, we directly compared cellular and humoral immune responses as well as neutralizing capacity against replication-competent SARS-CoV-2 wild type, Delta, and Omicron variants BA.1, BA.2, and BA.4/5. Methods Peripheral blood mononuclear cells and serum samples from 137 participants were investigated, in 3 major groups. Individuals in the first group were vaccinated twice with ChAdOx1 and boosted with a messenger RNA (mRNA) vaccine (BNT162b2 or mRNA-1273); the second group included triple mRNA-–vaccinated participants, and the third group, twice-vaccinated and convalescent individuals. Results Vaccination and convalescence resulted in the highest SARS-CoV-2–specific antibody levels, stronger T-cell responses, and best neutralization against wild type, Delta Omicron BA.2, and BA.4/5, while a combination of ChAdOx1 and BNT162b2 vaccination elevated neutralizing capacity against Omicron BA.1. In addition, heterologous booster regimens, compared with homologous regimens, showed higher efficacy against Omicron BA.2 as well as BA.4/5. Conclusions We showed that twice-vaccinated and convalescent individuals demonstrated the strongest immunity against Omicron BA.2 and BA.4/5 variant, followed by those receiving heterologous and homologous booster vaccine regimens. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Persistent Symptoms and IFN-γ-Mediated Pathways after COVID-19.
- Author
-
Piater, Talia, Gietl, Mario, Hofer, Stefanie, Gostner, Johanna M., Sahanic, Sabina, Tancevski, Ivan, Sonnweber, Thomas, Pizzini, Alex, Egger, Alexander, Schennach, Harald, Loeffler-Ragg, Judith, Weiss, Guenter, and Kurz, Katharina
- Subjects
AMINO acid metabolism ,SLEEP interruptions ,COVID-19 ,FATIGUE (Physiology) ,PHYSICAL mobility - Abstract
After COVID-19, patients have reported various complaints such as fatigue, neurological symptoms, and insomnia. Immune-mediated changes in amino acid metabolism might contribute to the development of these symptoms. Patients who had had acute, PCR-confirmed COVID-19 infection about 60 days earlier were recruited within the scope of the prospective CovILD study. We determined the inflammatory parameters and alterations in tryptophan and phenylalanine metabolism in 142 patients cross-sectionally. Symptom persistence (pain, gastrointestinal symptoms, anosmia, sleep disturbance, and neurological symptoms) and patients' physical levels of functioning were recorded. Symptoms improved in many patients after acute COVID-19 (n = 73, 51.4%). Still, a high percentage of patients had complaints, and women were affected more often. In many patients, ongoing immune activation (as indicated by high neopterin and CRP concentrations) and enhanced tryptophan catabolism were found. A higher phenylalanine to tyrosine ratio (Phe/Tyr) was found in women with a lower level of functioning. Patients who reported improvements in pain had lower Phe/Tyr ratios, while patients with improved gastrointestinal symptoms presented with higher tryptophan and kynurenine values. Our results suggest that women have persistent symptoms after COVID-19 more often than men. In addition, the physical level of functioning and the improvements in certain symptoms appear to be associated with immune-mediated changes in amino acid metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study.
- Author
-
Sonnweber, Thomas, Grubwieser, Philipp, Pizzini, Alex, Boehm, Anna, Sahanic, Sabina, Luger, Anna, Schwabl, Christoph, Widmann, Gerlig, Egger, Alexander, Hoermann, Gregor, Wöll, Ewald, Puchner, Bernhard, Kaser, Susanne, Theurl, Igor, Nairz, Manfred, Tymoszuk, Piotr, Weiss, Günter, Joannidis, Michael, Löffler-Ragg, Judith, and Tancevski, Ivan
- Subjects
COVID-19 ,METABOLIC disorders ,NEUROENDOCRINE cells ,COHORT analysis ,LONGITUDINAL method - Abstract
The severity of coronavirus disease 2019 (COVID-19) is related to the presence of comorbidities including metabolic diseases. We herein present data from the longitudinal prospective CovILD trial, and investigate the recovery from COVID-19 in individuals with dysglycemia and dyslipidemia. A total of 145 COVID-19 patients were prospectively followed and a comprehensive clinical, laboratory and imaging assessment was performed at 60, 100, 180, and 360 days after the onset of COVID-19. The severity of acute COVID-19 and outcome at early post-acute follow-up were significantly related to the presence of dysglycemia and dyslipidemia. Still, at long-term follow-up, metabolic disorders were not associated with an adverse pulmonary outcome, as reflected by a good recovery of structural lung abnormalities in both, patients with and without metabolic diseases. To conclude, dyslipidemia and dysglycemia are associated with a more severe course of acute COVID-19 as well as delayed early recovery but do not impair long-term pulmonary recovery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Vaccine based on folded receptor binding domain‐PreS fusion protein with potential to induce sterilizing immunity to SARS‐CoV‐2 variants.
- Author
-
Gattinger, Pia, Kratzer, Bernhard, Tulaeva, Inna, Niespodziana, Katarzyna, Ohradanova‐Repic, Anna, Gebetsberger, Laura, Borochova, Kristina, Garner‐Spitzer, Erika, Trapin, Doris, Hofer, Gerhard, Keller, Walter, Baumgartner, Isabella, Tancevski, Ivan, Khaitov, Musa, Karaulov, Alexander, Stockinger, Hannes, Wiedermann, Ursula, Pickl, Winfried F., and Valenta, Rudolf
- Subjects
CHIMERIC proteins ,SARS-CoV-2 ,BACTERIAL vaccines ,SARS-CoV-2 Omicron variant ,DNA vaccines ,COVID-19 pandemic - Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is responsible for the ongoing global COVID‐19 pandemic. One possibility to control the pandemic is to induce sterilizing immunity through the induction and maintenance of neutralizing antibodies preventing SARS‐CoV‐2 from entering human cells to replicate in. Methods: We report the construction and in vitro and in vivo characterization of a SARS‐CoV‐2 subunit vaccine (PreS‐RBD) based on a structurally folded recombinant fusion protein consisting of two SARS‐CoV‐2 Spike protein receptor‐binding domains (RBD) fused to the N‐ and C‐terminus of hepatitis B virus (HBV) surface antigen PreS to enable the two unrelated proteins serving as immunologic carriers for each other. Results: PreS‐RBD, but not RBD alone, induced a robust and uniform RBD‐specific IgG response in rabbits. Currently available genetic SARS‐CoV‐2 vaccines induce mainly transient IgG1 responses in vaccinated subjects whereas the PreS‐RBD vaccine induced RBD‐specific IgG antibodies consisting of an early IgG1 and sustained IgG4 antibody response in a SARS‐CoV‐2 naive subject. PreS‐RBD‐specific IgG antibodies were detected in serum and mucosal secretions, reacted with SARS‐CoV‐2 variants, including the omicron variant of concern and the HBV receptor‐binding sites on PreS of currently known HBV genotypes. PreS‐RBD‐specific antibodies of the immunized subject more potently inhibited the interaction of RBD with its human receptor ACE2 and their virus‐neutralizing titers (VNTs) were higher than median VNTs in a random sample of healthy subjects fully immunized with registered SARS‐CoV‐2 vaccines or in COVID‐19 convalescent subjects. Conclusion: The PreS‐RBD vaccine has the potential to serve as a combination vaccine for inducing sterilizing immunity against SARS‐CoV‐2 and HBV by stopping viral replication through the inhibition of cellular virus entry. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. The Impact of Iron Dyshomeostasis and Anaemia on Long-Term Pulmonary Recovery and Persisting Symptom Burden after COVID-19: A Prospective Observational Cohort Study.
- Author
-
Sonnweber, Thomas, Grubwieser, Philipp, Sahanic, Sabina, Böhm, Anna Katharina, Pizzini, Alex, Luger, Anna, Schwabl, Christoph, Koppelstätter, Sabine, Kurz, Katharina, Puchner, Bernhard, Sperner-Unterweger, Barbara, Hüfner, Katharina, Wöll, Ewald, Nairz, Manfred, Widmann, Gerlig, Tancevski, Ivan, Löffler-Ragg, Judith, and Weiss, Günter
- Subjects
IRON deficiency anemia ,COVID-19 ,IRON deficiency ,ANEMIA ,SYMPTOMS ,INTERSTITIAL lung diseases ,COHORT analysis - Abstract
Coronavirus disease 2019 (COVID-19) is frequently associated with iron dyshomeostasis. The latter is related to acute disease severity and COVID-19 convalescence. We herein describe iron dyshomeostasis at COVID-19 follow-up and its association with long-term pulmonary and symptomatic recovery. The prospective, multicentre, observational cohort study "Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (CovILD)" encompasses serial extensive clinical, laboratory, functional and imaging evaluations at 60, 100, 180 and 360 days after COVID-19 onset. We included 108 individuals with mild-to-critical acute COVID-19, whereas 75% presented with severe acute disease. At 60 days post-COVID-19 follow-up, hyperferritinaemia (35% of patients), iron deficiency (24% of the cohort) and anaemia (9% of the patients) were frequently found. Anaemia of inflammation (AI) was the predominant feature at early post-acute follow-up, whereas the anaemia phenotype shifted towards iron deficiency anaemia (IDA) and combinations of IDA and AI until the 360 days follow-up. The prevalence of anaemia significantly decreased over time, but iron dyshomeostasis remained a frequent finding throughout the study. Neither iron dyshomeostasis nor anaemia were related to persisting structural lung impairment, but both were associated with impaired stress resilience at long-term COVID-19 follow-up. To conclude, iron dyshomeostasis and anaemia are frequent findings after COVID-19 and may contribute to its long-term symptomatic outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study.
- Author
-
Rass, Verena, Beer, Ronny, Schiefecker, Alois Josef, Kofler, Mario, Lindner, Anna, Mahlknecht, Philipp, Heim, Beatrice, Limmert, Victoria, Sahanic, Sabina, Pizzini, Alex, Sonnweber, Thomas, Tancevski, Ivan, Scherfler, Christoph, Zamarian, Laura, Bellmann‐Weiler, Rosa, Weiss, Günter, Djamshidian, Atbin, Kiechl, Stefan, Seppi, Klaus, and Loeffler‐Ragg, Judith
- Subjects
MENTAL illness ,COVID-19 ,MELAS syndrome ,QUALITY of life ,NEUROLOGICAL disorders ,NEUROLOGIC manifestations of general diseases ,PSYCHOLOGICAL manifestations of general diseases - Abstract
Background and purpose: To assess neurological manifestations and health‐related quality of life (QoL) 3 months after COVID‐19. Methods: In this prospective, multicenter, observational cohort study we systematically evaluated neurological signs and diseases by detailed neurological examination and a predefined test battery assessing smelling disorders (16‐item Sniffin Sticks test), cognitive deficits (Montreal Cognitive Assessment), QoL (36‐item Short Form), and mental health (Hospital Anxiety and Depression Scale, Posttraumatic Stress Disorder Checklist–5) 3 months after disease onset. Results: Of 135 consecutive COVID‐19 patients, 31 (23%) required intensive care unit (ICU) care (severe), 72 (53%) were admitted to the regular ward (moderate), and 32 (24%) underwent outpatient care (mild) during acute disease. At the 3‐month follow‐up, 20 patients (15%) presented with one or more neurological syndromes that were not evident before COVID‐19. These included polyneuro/myopathy (n = 17, 13%) with one patient presenting with Guillain‐Barré syndrome, mild encephalopathy (n = 2, 2%), parkinsonism (n = 1, 1%), orthostatic hypotension (n = 1, 1%), and ischemic stroke (n = 1, 1%). Objective testing revealed hyposmia/anosmia in 57/127 (45%) patients at the 3‐month follow‐up. Self‐reported hyposmia/anosmia was lower (17%) at 3 months, however, improved when compared to the acute disease phase (44%; p < 0.001). At follow‐up, cognitive deficits were apparent in 23%, and QoL was impaired in 31%. Assessment of mental health revealed symptoms of depression, anxiety, and posttraumatic stress disorders in 11%, 25%, and 11%, respectively. Conclusions: Despite recovery from the acute infection, neurological symptoms were prevalent at the 3‐month follow‐up. Above all, smelling disorders were persistent in a large proportion of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.